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Abstract
Background: We aimed to determine the mutation yield and clinical applicability of “molecular autopsy” following
sudden arrhythmic death syndrome (SADS) by validating and utilizing low-cost high-throughput technologies:
Fluidigm Access Array PCR-enrichment with Illumina HiSeq 2000 next generation sequencing (NGS).
Methods: We validated and optimized the NGS platform with a subset of 46 patients by comparison with Sanger
sequencing of coding exons of major arrhythmia risk-genes (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, RYR2). A
combined large multi-ethnic international SADS cohort was sequenced utilizing the NGS platform to determine
overall molecular yield; rare variants identified by NGS were subsequently reconfirmed by Sanger sequencing.
Results: The NGS platform demonstrated 100% sensitivity for pathogenic variants as well as 87.20% sensitivity and
99.99% specificity for all substitutions (optimization subset, n = 46). The positive predictive value (PPV) for NGS for
rare substitutions was 16.0% (27 confirmed rare variants of 169 positive NGS calls in 151 additional cases). The
overall molecular yield in 197 multi-ethnic SADS cases (mean age 22.6 ± 14.4 years, 68% male) was 5.1% (95%
confidence interval 2.0–8.1%), representing 10 cases carrying pathogenic or likely pathogenic risk-mutations.
Conclusions: Molecular autopsy with Fluidigm Access Array and Illumina HiSeq NGS utilizing a selected panel of
LQTS/BrS and CPVT risk-genes offers moderate diagnostic yield, albeit requiring confirmatory Sanger-sequencing of
mutational variants.
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Background
Premature unexpected and unexplained sudden cardiac
deaths (SCD) with normal autopsy and toxicology are
referred to as sudden arrhythmic death syndrome
(SADS) [1, 2], which affects between 0.24 and 0.81 per
100,000 young adults per year in Europe [3]. Contem-
poraneous epidemiological studies of young SCD (under
age 35 years) identify SADS as the commonest certifiable
cause in western populations, constituting up to 40% in
some series [3–5], although the estimated incidence of
SADS is dependent on study design and autopsy proto-
col [6]. Inherited cardiac ion channel disease, such as
the long QT syndrome (LQTS) and Brugada syndrome
(BrS) can be identified in up to half of the families of
SADS cases [1, 7]. This diagnostic yield of cardiological
evaluation, while clinically important in identifying sur-
viving family at risk is limited by incomplete penetrance
[7]. Genetic mutation analysis on post-mortem DNA,
known as the molecular autopsy, has the potential to
identify disease-associated (pathogenic) mutations re-
sponsible for SADS, regardless of expressivity; this
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approach is recommended if provided with appropriate
genetic counseling for blood relatives [6, 8].
A yield of 19–26% mutations in LQTS, BrS and catechol-
aminergic polymorphic ventricular tachycardia (CPVT)
risk-genes has been established by 2 large molecular
autopsy SADS series from USA [9, 10]; population-based
Australasian studies identified yields of up to 27% using ex-
ome-based methodology which included analysis of less
common arrhythmia and cardiomyopathy-risk genes
[4, 11]. Use of formalin-fixed, paraffin-embedded tis-
sue for DNA extraction and limited candidate gene
panels have reduced yields in other series [3].
Despite a class IIa recommendation [2, 12], molecular
autopsy is infrequently utilized, with monetary cost
given as one of the main reasons for failing to do so
[13]. Next generation sequencing (NGS) technologies
may offer inexpensive methods to overcome financial
limitations. Multiplexed PCR-based candidate gene
enrichment seen in the Access Array (Fluidigm Corpor-
ation, San Francisco) may be appropriate for the moder-
ate genetic target size recommended for molecular
autopsy following SADS [14]. This can be coupled with
NGS by the HiSeq 2000 (Illumina Inc., San Diego) to
provide a low-cost high-throughput candidate gene NGS
platform.
We aimed to quantify the diagnostic yield of molecular
autopsy identified by this NGS (Fluidigm/Illumina) plat-
form in major candidate risk-genes implicated in LQTS,
BrS and CPVT in a cohort of international and multi-
ethnic SADS cases. The NGS platform was validated on
a population-based Caucasian subset of British SADS
cases. We evaluated our NGS platform’s future clinical
utility for investigation of SADS.
Methods
Study setting
We included cases from two cohorts (British Optimization
Cohort and International Cohort) which fulfilled the def-
inition of SADS: SCD aged 1–64 years; no ante-mortem
cardiac history; last seen alive and well within 24 h of
being found dead; no identified cause of death on toxico-
logical analysis and comprehensive coronial and cardiac
autopsy [1, 7, 15]. Demographic characteristics, symp-
toms, medical and family history of SADS cases were
ascertained by direct contact with next of kin where
consent was given, and from coroners’ and pathologists’
reports.
Study cohorts
British SADS optimization cohort
Consecutive unexpected Caucasian SCD cases requiring
coronial autopsy (n = 115) were referred by coroners
over 12 months, as part of a previously reported national
study (1998 to 1999) [15]. Expert panel confirmed SADS
in 56 cases; 46 (82.1%) cases had suitable DNA for inclu-
sion extracted from frozen blood. Whole-genome ampli-
fication of DNA with commercial kits was utilized prior
to sequencing. Conventional mutation detection with
Sanger sequencing and NGS with Fluidigm/Illumina
were performed in parallel to optimize the NGS plat-
form on this cohort.
International SADS cohort
Unrelated SADS cases (n = 174) where frozen blood
and/or tissue was available were included; no cases with
DNA extracted from neonatal blood spot were included.
Suitable DNA was extracted from 151 (86.8%) included
cases. This multi-ethnic international cohort was re-
cruited from: population-based coronial series (Cardiac
Inherited Disease Registry, Auckland, New Zealand
2000–2009 [11, 16], n = 63; SCD Registry, Denmark
2000–2006 [5], n = 26); consecutive referrals for autopsy
(Royal Brompton Hospital, London 2007–2011, n = 19;
Sheffield Children’s Hospital 1985–2001, n = 19); and
consecutive referrals for familial cardiac evaluation (St
George’s or Lewisham Hospitals, London 2009–2011,
n = 28; Academic Medical Centre, Amsterdam 1995–
2011 [17], n = 19). Eleven previously published cases
from the New Zealand cohort were diagnosed with LQTS
on the basis of variants in LQTS risk-genes following mo-
lecular autopsy with Sanger sequencing [11, 16]. Nine of
these cases were not included in the analysis (including
RYR2 mutation analysis), while two were included as
positive controls. This cohort underwent NGS with the
Fluidigm/Illumina platform as described below; indels and
structural variants were not evaluated.
Genetic mutation analysis
The arrhythmia panel consisted of coding exons and in-
tron/exon boundaries of risk-genes for development of
LQTS, BrS and CPVT [18–20]: KCNQ1, KCNH2, SCN5A,
KCNE1, KCNE2 and RYR2.
Conventional mutation detection with sanger sequencing
Sequence-specific oligonucleotide primers amplified all
LQTS and BrS risk-genes (KCNQ1, KCNH2, SCN5A,
KCNE1, KCNE2) targets before direct sequencing
(ABI3730 sequencer, Life Technologies, California). For
the CPVT risk-gene RYR2, we individually screened 37
prioritized exons (7–9, 13–16, 43–50, 82–84, 87–105)
with single strand conformational analysis (SSCA);
amplicons demonstrating abnormal conformation were
subsequently sequenced selectively with an ABI3730 se-
quencer (Life Technologies).
Next generation sequencing with Fluidigm / Illumina
Custom-designed primer pairs to target all candidate
gene exons and splice-sites (including RYR2) were
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designed and optimized for the Fluidigm Access Array
[21]. Manufacturer’s protocols (Fluidigm 48.480) were
followed to amplify genomic DNA in up to 10-plex PCR
reaction wells; subsequently, barcode indexes and se-
quencing adaptors were added by further PCR. Pooled
amplicons were harvested and diluted to prepare unidir-
ectional libraries for 150 base-pair (bp) paired-end se-
quencing on Illumina HiSeq 2000. Illumina NGS reads
were trimmed for base Phred quality control (mean
quality in a 30 bp sliding window > 20 and 3′ base qual-
ity ≥6) and aligned with BWA (v0.6.1-r112-master) on
hg19 human genome reference sequence. Variant-calling
was performed using GATK v1.5 (Genome Analysis
Toolkit, Broad Institute, Cambridge, USA) [22] without
downsampling or removal of PCR duplicates; variants
with quality/depth < 5 or depth < 30 were filtered. Identi-
fied rare missense exonic or splice-site substitutions
were confirmed by conventional PCR amplification and
ABI3730 sequencing.
Analysis of rare genetic variation
Variants were considered rare if non-synonymous or af-
fecting splice sites (±5 bp intron/exon boundary) and
demonstrated allele frequency < 0.5% in the ExAC [23]
and GO-ESP multiethnic exome databases [24], as iden-
tified from the ExAC Browser [25] and The Exome Vari-
ant Server [24] respectively. Variants were named
according to HGVS recommendations; correct naming
was confirmed by use of Mutalyzer [26, 27]. All rare var-
iants were submitted to the in silico predictions servers:
PolyPhen [28], SIFT, [29, 30] MutationTaster [31, 32]
and MutationAssessor [33] for interpretation. Addition-
ally, classifications were extracted from ClinVar [34].
Conservation was assessed by BLAST and CLUSTAL
OMEGA. Finally, rare variants were classified as “patho-
genic”, “likely pathogenic”, “benign”, “likely benign” or
“uncertain significance” in line with current American
College of Medical Genetics (ACMG) guidelines [35];
rare variants were considered disease-associated muta-
tions if classified as pathogenic or likely pathogenic.
Optimization of NGS
NGS (Fluidigm / Illumina) was compared to the “gold-
standard” of conventional PCR and Sanger sequencing,
based on LQTS and BrS risk-gene (KCNQ1, KCNH2,
SCN5A, KCNE1, KCNE2) common and rare variation
identified in the British SADS Optimization Cohort. This
represents the entirety of the population-based UK series
of SADS cases. RYR2 data was not included due to
SSCA use and incomplete exon coverage.
Statistics
Data are expressed as means and standard deviation.
Normal approximation interval provides 95% confidence
interval CI for yield. Comparison of proportions and
means are made with Fisher’s exact and t-test respect-
ively, with p < 0.05 considered significant.
Results
A total of 197 SADS cases (mean age 22.6 ± 14.4 years,
68% male) were analyzed by combining the British and
International cohorts (Fig. 1). There was no difference in
proportion of exertional deaths between gender groups
or age cohort (p = 0.07 and p = 1.00 respectively; Fig. 2).
Twenty-six different rare variants were identified in 29
cases (Table 1). Two individuals were double heterozy-
gotes, while one rare variant was identified in six unre-
lated individuals (see Ethnic Variant Analysis below).
Detailed variant assessment for ACMG classification of
pathogenicity is provided as Additional file 1. A sum-
mary of demographic characteristics of carriers of dis-
ease-associated mutations is given in Fig. 3.
British SADS optimization cohort
Mean age of the 46 SADS cases was 32.9 ± 14.4 years,
comprising 59% males and 28 (61%) non-exertional
deaths. Five (11%) families received a clinical diagnosis
of genetic disease, as previously reported [1, 15]. Four
rare exonic missense variants were identified in four
cases; two were disease-associated mutations (variants C
and V in Table 1). None of the five cases whose families
were diagnosed with inherited heart disease were found
to carry any rare variants in the genes sequenced [1, 15].
Clinical diagnostic yield of a disease-related mutation
was identified in 4.3% (n = 2/46; 95% CI 0.0–10.2%).
Performance of NGS platform
All samples in the Optimization Cohort had greater than
95% coverage at depth of 10x of the 27049 bp target
(KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, total 171
amplicons). Mean depth was 3382 reads. Sensitivity for
any base change (synonymous or non-synonymous sub-
stitution or splice-site variant) for the regions that could
be assessed was 87.20% (39 unique variants identified by
Sanger sequencing within the target); five amplicons
failed amplification. Specificity was 99.99%. Importantly,
NGS demonstrated 100% sensitivity for the rare mis-
sense variants (n = 4). The International Cohort identi-
fied the PPV for correctly identifying any rare variation
by NGS was 16.0% (27 true positive confirmed by Sanger
sequencing of 169 positive calls by NGS platform).
Ethnic variants
Six New Zealand cases carried the splice-site variant of
uncertain significance c.10231-4 T > C (rs117180147) in
RYR2 (NM_001035.2), with five being of Maori ancestry.
This variant has no effect on essential splice donor or
acceptor bases and is present rarely in East Asians
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(1.28%), but not seen in Caucasians [24, 36]. No Maori
control data was available for comparison.
Disease-associated mutations
Ten rare variants were pathogenic or likely pathogenic
and therefore considered disease-associated (Table 1).
The majority of these were missense mutations (n = 9),
with 1 truncation. This represents 10 SADS cases (5.1%);
no disease-associated mutations were seen in more than
1 SADS case. A greater prevalence of mutations amongst
female cases was seen with respect to LQTS/BrS risk-
mutations (p = 0.03), though no significant difference
was seen when considering all risk-genes (including
RYR2, p = 0.73). No difference in mutation carrier status
was seen between adults and children (p = 0.33).
Pathogenicity of LQTS/BrS risk-mutations
Fifteen rare variants were identified in LQTS/BrS risk-
genes, with three disease-associated. Two were reported
as previously associated with disease: KCNH2 (NM_
000238.3) N-terminus variant p.G71R associated with
LQTS type 2 [37]; SCN5A (NM_198056.2) variant
p.T220I located in the first transmembrane domain
(a region associated with high probability of pathogen-
icity) [18] which demonstrates in-vitro sodium channel
dysfunction [38] and co-segregation with dilated cardio-
myopathy and heart block [39]. A novel truncation
p.W323* was detected in KCNQ1 and predicted to cause
nonsense-mediated decay [40]. Neither rare variant in
KCNE1 and KCNE2 were likely to be pathogenic by
ACMG criteria.
Pathogenicity of RYR2 risk-mutations
The 10 rare variants in RYR2 (excluding the likely ethnic
Maori splicing variant c.10231-4 T > C) lie within 10
different exons (7, 14, 37, 38, 47, 49, 54, 74, 88 and 95).
Seven were categorised as disease-associated muta-
tions. Five variants (p.R420Q, p.R2401H, p.G3946S
and p.R4608Q) were categorised as disease-causing by
HGMD, demonstrated 100% mammalian conservation
and were previously reported [20, 41]; two other vari-
ants (p.T153I, p.G1750R) fulfilled ACMG criteria for
likely pathogenicity based on in-silico predictions and
conservation data.
A
B
Fig. 1 Age Distribution of SADS Cases. Histograms demonstrating bimodal age (years) distribution of all SADS cases included, plotted by gender
([a] Male and [b] Female). Mean ages indicated by vertical dotted gold lines
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Clinical diagnostic yield
Pathogenic or likely-pathogenic disease-associated muta-
tions in major arrhythmia syndrome risk-genes were
identified in 10 of 197 multi-ethnic SADS cases. This
represents a diagnostic yield of 5.1% (95% CI 2.0–8.1%).
Discussion
This study reports on utility of a low-cost high-through-
put PCR-based next generation sequencing molecular
autopsy in a multi-ethnic internationally recruited series
of SADS cases.
Diagnostic yield of molecular autopsy in SADS
Our multi-ethnic international cohort data support a
clinical diagnostic yield for molecular autopsy of SADS
cases of up to 5.1% amongst recognized major ion-chan-
nelopathy risk-genes, less than that from similarly-sized
US studies [9, 10]. The Australasian population-based
series of 113 cases demonstrated a comparable yield of
8.8% pathogenic and probably pathogenic mutations uti-
lising NGS [4]. Our prior report (which overlaps with
this study cohort) revealed a clinically relevant yield of
10.6% from the common risk-genes studied here, but
differs by its use of hybridization-based NGS [17].
Although Wang et al. [10] report on a multi-ethnic
SADS population from New York, our study is multi-
centre and international. Hence, it remains unclear
whether these differences in yield relate to: our complete
use of PCR-based NGS as a primary diagnostic genetic
methodology; definitions of pathogenicity; ethnicity
differences; or local referral bias.
Potential role of NGS in SADS
NGS has been used for investigation of large SADS co-
horts for partial coverage of SCN5A as part of a larger
Sanger sequencing study [10], and exome or clinical
NGS sequencing in Australasian [4], French [42] and
UK [43] series in addition to our previous report [17].
NGS permits use of less DNA and confers greater gen-
etic coverage than conventional technology, which is of
particular importance in post-mortem cases where good
quality genomic DNA is finite. Moreover, NGS amplifi-
cation technologies are less labor intensive than Sanger
sequencing.
Microfluidic muliplex PCR-based enrichment of candi-
date genes for NGS (i.e. Fluidigm) offers a balance of
throughput and cost-efficiency [21]. Specifically, it offers
targeted sequencing which is an order of magnitude
A
B
Fig. 2 Circumstances of Death amongst SADS Cases. Pie charts demonstrating activity and circumstances at time of death plotted by [a] gender
and [b] age group (children are aged under 18 years)
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cheaper than hybridization capture (e.g. SureSelect, Agi-
lent, Santa Clara, California): approximately $25USD
versus $200USD for capture and sequencing.
RYR2 mutation analysis
Our RYR2 yield (3.6%, n = 7/197) represents over half
the clinically-relevant molecular yield, and falls within
the range of yields from previously reported large series
from USA and Australasia: 3.0% (n = 4/133) [10]; 3.5%
(n = 4/113) [4]; and 11.6% (n = 20/173) [9]. The complete
sequencing of RYR2 with NGS appears to contribute
additional yield over limited exon-targeted approaches
[9]; 20% (n = 2/10) of our RYR2 rare variants lay outside
the 64 sequenced exons described by Tester et al. [9]; 40%
(n = 4/10) would have been missed by a 3-tiered exon mu-
tation analysis strategy for CPVT diagnosis [20].
Cardiological evaluation of blood relatives
In our population-based British SADS Optimization
Cohort, where limited cardiac investigation of families
was performed, mutations were not identified in the five
SADS cases whose relatives were diagnosed with clinical
Table 1 Rare Variants identified in SADS Cases
SADS Case ID Variant HGMD ID dbSNP ID Transcript change Amino Acid change ACMG Classification
KCNE1 (NM_000219.5/NP_000210.2)
314 A rs75610894 c.142C > T p.L48F VUS
KCNE2 (NM_172201.1/NP_751951.1)
756 B CM003449 rs2234916 c.22A > G p.T8A VUS
KCNH2 (NM_000238.3/NP_000229.1)
998 C CM057124 rs199473420 c.211G > C p.G71R Likely Pathogenic
217 D CM002298 rs138776684 c.1039C > T p.P347S VUS
411 E c.2564G > A p.S855 N VUS
714 F CM057119 rs199473017 c.2903C > T p.P968L VUS
KCNQ1 (NM_000218.2/NP_000209.2)
907 G CM139859 rs794728567 c.969G > A p.W323* Likely Pathogenic
1006 H CM078293 rs12720457 c.1179G > C p.K393 N VUS
910 I rs199472783 c.1379G > A p.G460D VUS
1012 J rs794728542 c.1829C > A p.T610 N VUS
RYR2 (NM_001035.2 /NP_001026.2)
725 K rs766802574 c.458C > T p.T153I Likely Pathogenic
9 L CM097927 rs794728721 c.1259G > A p.R420Q Pathogenic
36 M c.5248G > A p.G1750R Likely Pathogenic
916 N rs397516546 c.5825 T > G p.F1942C VUS
306 O CM056049 rs794728756 c.7202G > A p.R2401H Likely Pathogenic
914 P rs377763795 c.7458 T > G p.H2486Q VUS
708# Q CM1515197 rs201500134 c.8162 T > C p.I2721T VUS
$ & R rs117180147 c.10231-4 T > C VUS
403 S c.10681C > G p.L3561 V Likely Pathogenic
759 T CM024349 rs794728777 c.11836G > A p.G3946S Pathogenic
38 U CM148846 c.13823G > A p.R4608Q Pathogenic
SCN5A (NM_198056.2/NP_932173.1)
1034 V CM033019 rs45620037 c.659C > T p.T220I Likely Pathogenic
746& W CM034060 rs36210423 c.1715C > A p.A572D Likely Benign
727 X rs72549411 c.2437-5C > A VUS
738 Y CM086913 rs41311117 c.6010 T > C p.F2004 L VUS
708# Z CM004144 rs45489199 c.6016C > G p.P2006A VUS
Details of multi-ethnic SADS cohort cases carrying rare variants in major ion channel disease risk-genes: HGMD and dbSNP identifier; transcript and amino acid
changes; pathogenicity of variant (ACMG criteria). Abbreviations: VUS = variant of uncertain significance. Annotations: $ = SADS cases 703, 715,722,731,745, 746;
#& = double heterozygotes for rare variation
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disease [1]. Molecular autopsy increased our yield of
genetic diagnoses (from 10.9 to 15.2%, n = 5 to 7). This
reinforces the complementary approaches of familial car-
diac investigation and molecular autopsy following a
SADS death [4, 11, 17].
Genetic ancestry and the interpretation of genetic results
The RYR2 splice site variant (c.10231-4 T > C) was
present in 5 of the 27 Maori/Polynesian cases. ExAC
identifies 1.28% minor allele frequency in East Asians for
this variant, and lower frequencies in African and Latino
populations. This is plausible as a risk factor for arrhythmic
death, similar to that seen with SCN5A-S1103Y in the Afri-
can-American population [44]. Similarly, SCN5A-R1193Q
has in vitro sodium channel dysfunction and associates
with channelopathic disease in Europeans [45], yet the
variant is common in Maori, and occurs in over 10% of the
Han Chinese [46]. With most studies focusing on ethnic
Europeans, there is a risk that other groups may be denied
the benefits of genetic diagnosis.
Clinical implications of the Fluidigm/Illumina NGS platform
Our PPV of 16% mandates approximately 6 variants to
be verified by Sanger sequencing for the detection of
one true mutation (i.e. five false positives for every
true rare variant), with no additional bioinformatics
optimization identified to improve this. We believe missed
common variants in amplified regions (>10x coverage) of
the Optimization Cohort related to preferential amplifica-
tion of one allele. These findings compare unfavourably
with application of this technology in living individuals
[14], and could be explained by increased PCR errors
encountered in use of lower quality post-mortem DNA.
This was supported by appearance of clustering of false
positive results in specific cases, suggestive of a DNA sam-
pling issue; no other specific features of false positives
were identified to assist in filtering them out. Notably,
preferential amplification of a single allele is a recognized
limitation of microfluidic PCR-based amplification due to
the number of PCR cycles required.
PCR errors are exacerbated by microfluidic technology
due to the greater requirement for amplification. Add-
itionally, PCR duplicates were not removed by bioinfor-
matic processing prior to variant calling; removal of
duplicates following PCR-based target selection would
serve to reduce depth of coverage uniformly to less than
10x, rendering variant calling even less reliable. Given
the low likelihood for identical PCR errors with repeti-
tion, false positives may be reduced by performing each
amplification (and subsequent NGS) in duplicate and
A
B
Fig. 3 Mutation Carriers amongst SADS cases. Bar charts demonstrating pathogenic and likely pathogenic mutation carriers plotted by [a] gender
and [b] age group (children are aged under 18 years). Abbreviations: BrS = Brugada syndrome; CPVT = catecholaminergic polymorphic ventricular
tachycardia; LQTS = long QT syndrome
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only considering variants to be present when identified
in both duplicates. However, this method would serve to
double the cost per sample of the Fluidigm/Illumina
platform in this context. Additionally, the impact on al-
lele amplification and subsequent sensitivity for rare
variant identification of this approach is unknown.
Though the financial advantage is being eroded by de-
clining cost of more precise capture technologies such
as hybridization [21], this NGS platform may remain
useful as an initial screening strategy until economic
costs become comparable. In comparison with limited
analysis of non-synonymous rare variants in the same
risk-genes, no additional clinically relevant variants
were identified by hybridization target selection meth-
odology in the 87 cases which overlapped with our
prior report [17].
Study limitations
This study did not analyze small insertions and dele-
tions; such structural rearrangements represent a minor-
ity of mutations, making up only 1 in 10 of those with
definite LQTS [47, 48]. Copy number variants were not
assessed; none were identified in the major risk-genes by
Bagnall et al. in their molecular autopsy study [4]. Simi-
larly, we did not address intronic mutations, which are
rare in clinical practice, and require large families for co-
segregation and in vitro study for confirmation of
clinical relevance [49, 50]. GATK v1.5 was used as the
updated open-source version available at the time of
bioinformatic optimization; we acknowledge that this
software has since been improved with respect to variant
calling which may further improve the diagnostic preci-
sion of the technology.
Clinical data pertaining to surviving blood relatives
was not studied systematically; co-segregation did not
contribute to novel mutation disease-causing status,
which is a significant limitation in the context of foren-
sic post-mortem mutation analysis. Although cardiomy-
opathy and other arrhythmia syndrome genes were not
evaluated, they are likely to contribute less significantly
to SADS and pose even greater uncertainty for patho-
genicity [4, 17, 43]. The cohort of New Zealand cases
was biased by exclusion of a majority (9 of 11) identified
LQTS-risk gene variant carriers; these cases did not
undergo RYR2 mutation analysis. Nonetheless, only
three would be classified pathogenic or likely pathogenic
by modern ACMG criteria, resulting in a minimally
affected molecular autopsy yield of 6.3% (n = 13/206) if
the study cohort was unselected.
Conclusion
The combination of Fluidigm Access Array with Illumina
HiSeq NGS to sequence a selected panel of LQTS/BrS
and CPVT risk-genes offers a moderate diagnostic yield of
5.1% amongst SADS cases. Although the low PPV
mandates confirmation of mutational variants by Sanger-
sequencing, molecular autopsy may also still add signifi-
cant yield to clinical evaluation of blood relatives.
Additional file
Additional file 1: Tables and References supporting ACMG classification
of variants identified. (PDF 811 kb)
Abbreviations
bp: Base pairs; BrS: Brugada syndrome; CI: Confidence interval;
CPVT: Catecholaminergic polymorphic ventricular tachycardia;
DNA: Deoxyribonucleic acid; LQTS: Long QT syndrome; NGS: Next generation
sequencing; PCR: Polymerase chain reaction; SADS: Sudden arrhythmic death
syndrome; SCD: Sudden cardiac death; SSCA: Single strand conformational
analysis
Acknowledgements
Dutch cases were studied within the framework of CTMM (Center for
Translational Molecular Medicine) project COHFAR. The Cardiac Inherited
Disease Registry New Zealand is supported by Cure Kids. Cases from New
Zealand were studied with the permission of the chief coroner for New
Zealand. This research has been conducted using the Danish National Biobank
resource, supported by the Novo Nordisk Foundation. The authors would like
to thank the Exome Aggregation Consortium and the groups that provided
exome variant data for comparison. A full list of contributing groups can be
found at http://exac.broadinstitute.org/about.
Authors’ contributions
HR and ERB conceived the study and were major contributors in writing the
manuscript. HR, JSW, JRS, PLH, GA, DRL, CVDW, JTH, BGW, MCC, XL, SJ, SS, SJ,
AAMW, MC, MNS and ERB contributed to data collection and initial analysis.
HR, JSW, PH, GA and MC performed variant data analysis. HR, JSW, JRS, PLH,
GA, DRL, CVDW, JTH, BGW, MCC, XL, SJ, SS, SJ, AAMW, MC, MNS and ERB
read and approved the final manuscript.
Funding
The project was funded by British Heart Foundation Fellowship Grant FS/11/
71/28918; the funding body had no influence on design of the study,
collection, analysis, and interpretation of data or writing the manuscript. We
acknowledge additional support from: Cardiac Risk in the Young (ERB, HR,
MNS, SS); Netherlands CardioVascular Research Initiative, the Dutch Heart
Foundation, Dutch Federation of University Medical Centres, the Netherlands
Organisation for Health Research and Development and the Royal
Netherlands Academy of Sciences (AAMW, CvdW); Wellcome Trust (JSW).
Availability of data and materials
Rare variant data analysed during this study are included in this published
article and its supplementary information files. The raw datasets are not
publicly available, but are available from the corresponding author on
reasonable request.
Ethics approval and consent to participate
The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in a priori approval by the Research Ethics
Service Wandsworth (Ref 10H/0803/72); written consent was provided by
next of kin for participation.
Consent for publication
Not applicable.
Competing interests
ERB has received independent research grants from Biotronik and St Jude
Medical.
Raju et al. BMC Cardiovascular Disorders          (2019) 19:174 Page 8 of 10
Author details
1Cardiovascular Sciences Research Centre, Molecular and Clinical Sciences
Research Institute, St George’s University of London, London SW17 0RE, UK.
2Health Cardiology, Faculty of Medicine & Health Sciences, Macquarie
University, Suite 203, 2 Technology Place, Sydney, NSW 2109, Australia. 3NIHR
Royal Brompton Cardiovascular Biomedical Research Unit, Royal Brompton
Hospital, London, UK. 4Greenlane Paediatric and Congenital Cardiac Services,
Starship Childrens Hospital, Auckland, New Zealand. 5Department for
Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.
6Diagnostic Genetics, Auckland City Hospital, Auckland, New Zealand.
7Amsterdam UMC, Heart Centre, and Department of Clinical and
Experimental Cardiology, Amsterdam Cardiovascular Sciences, University of
Amsterdam, Amsterdam, Netherlands. 8Department of Cardiology,
Copenhagen University Hospital, Rigshospitalet, Denmark. 9Department of
Forensic Medicine, University of Copenhagen, København, Denmark.
10Histopathology Department, Sheffield Children’s Hospital, Sheffield, UK.
11School of Science, Engineering and Design, Teesside University,
Middlesbrough, UK. 12ERN-GUARD Heart (European Union), Brussels, Belgium.
13Department of Biomedical Sciences, University of Copenhagen,
Copenhagen, Denmark.
Received: 7 April 2018 Accepted: 10 July 2019
References
1. Behr E, Wood DA, Wright M, Syrris P, Sheppard MN, Casey A, et al.
Cardiological assessment of first-degree relatives in sudden arrhythmic
death syndrome. Lancet. 2003;362:1457–9.
2. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. Executive
summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis
and management of patients with inherited primary arrhythmia syndromes.
Europace. 2013;15:1389–406.
3. Raju H, Behr ER. Unexplained sudden death, focussing on genetics and
family phenotyping. Curr Opin Cardiol. 2013;28:19–25.
4. Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, et al. A
prospective study of sudden cardiac death among children and young
adults. N Engl J Med. 2016;374:2441–52.
5. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.
Nationwide study of sudden cardiac death in persons aged 1-35 years. Eur
Heart J. 2011;32:983–90.
6. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al.
Guidelines for autopsy investigation of sudden cardiac death: 2017 update
from the Association for European Cardiovascular Pathology. Virchows Arch
Int J Pathol. 2017; epub prior to publication.
7. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome
Esteban MT, et al. Sudden arrhythmic death syndrome: familial
evaluation identifies inheri heart disease in the majority of families. Eur
Heart J. 2008;29:1670–80.
8. Campuzano O, Allegue C, Partemi S, Iglesias A, Oliva A, Brugada R. Negative
autopsy and sudden cardiac death. Int J Legal Med. 2014;128:599–606.
9. Tester DJ, Medeiros-Dtableomingo A, Will ML, Haglund CM, Ackerman MJ.
Cardiac channel molecular autopsy: insights from 173 consecutive cases of
autopsy-negative sudden unexplained death referred for postmortem
genetic testing. Mayo Clin Proc Mayo Clin. 2012;87:524–39.
10. Wang D, Shah KR, Um SY, Eng LS, Zhou B, Lin Y, et al. Cardiac
channelopathy testing in 274 ethnically diverse sudden unexplained deaths.
Forensic Sci Int. 2014;237:90–9.
11. Skinner JR, Crawford J, Smith W, Aitken A, Heaven D, Evans C-A, et al.
Prospective, population-based long QT molecular autopsy study of postmortem
negative sudden death in 1 to 40 year olds. Heart Rhythm. 2011;8:412–9.
12. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm
J, et al. 2015 ESC guidelines for the management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death: the
task force for the Management of Patients with ventricular arrhythmias and
the prevention of sudden cardiac death of the European Society of
Cardiology (ESC). Endorsed by: Association for European Paediatric and
Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.
13. Michaud K, Mangin P, Elger BS. Genetic analysis of sudden cardiac death
victims: a survey of current forensic autopsy practices. Int J Legal Med. 2011;
125:359–66.
14. Li X, Buckton AJ, Wilkinson SL, John S, Walsh R, Novotny T, et al. Towards
clinical molecular diagnosis of inherited cardiac conditions: a comparison of
bench-top genome DNA sequencers. PLoS One. 2013;8:e67744.
15. Behr ER, Casey A, Sheppard M, Wright M, Bowker TJ, Davies MJ, et al.
Sudden arrhythmic death syndrome: a national survey of sudden
unexplained cardiac death. Heart. 2007;93:601–5.
16. Gladding PA, Evans C-A, Crawford J, Chung SK, Vaughan A, Webster D, et al.
Posthumous diagnosis of long QT syndrome from neonatal screening cards.
Heart Rhythm. 2010;7:481–6.
17. Lahrouchi N, Raju H, Lodder EM, Papatheodorou E, Ware JS, Papadakis M, et
al. Utility of post-mortem genetic testing in cases of sudden arrhythmic
death syndrome. J Am Coll Cardiol. 2017;69:2134–45.
18. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, et al.
Genetic testing for long-QT syndrome: distinguishing pathogenic mutations
from benign variants. Circulation. 2009;120:1752–60.
19. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, et
al. Spectrum and prevalence of mutations from the first 2,500 consecutive
unrelated patients referred for the FAMILION long QT syndrome genetic
test. Heart Rhythm. 2009;6:1297–303.
20. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van
Tintelen JP, et al. The RYR2-encoded ryanodine receptor/calcium release
channel in patients diagnosed previously with either catecholaminergic
polymorphic ventricular tachycardia or genotype negative, exercise-induced
long QT syndrome: a comprehensive open reading frame mutational
analysis. J Am Coll Cardiol. 2009;54:2065–74.
21. Ware JS, John S, Roberts AM, Buchan R, Gong S, Peters NS, et al. Next
generation diagnostics in inherited arrhythmia syndromes : a comparison of
two approaches. J Cardiovasc Transl Res. 2013;6:94–103.
22. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al.
The genome analysis toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res. 2010;20:1297–303.
23. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al.
Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;
536:285–91.
24. Exome Variant Server [Internet]. The goal of the NHLBI GO Exome Sequencing
Project (ESP) is to discover novel genes and mechanisms contributing to heart,
lung and blood disorders by pioneering the application of next-generation
sequencing of the protein coding regions of the human genome across
diverse, richly-phenotyped populations and to share these datasets and
findings with the scientific community to extend and enrich the diagnosis,
management and treatment of heart, lung and blood disorders. [cited 2017
Mar 5]. Available from: http://evs.gs.washington.edu/EVS/.
25. ExAC Browser [Internet]. The data set provided on this website spans 60,706
unrelated individuals sequenced as part of various disease-specific and
population genetic studies. [cited 2017 Mar 5]. Available from: http://exac.
broadinstitute.org/
26. Wildeman M, Ophuizen EV, van Ophuizen E, den Dunnen JT, Taschner PEM.
Improving sequence variant descriptions in mutation databases and
literature using the Mutalyzer sequence variation nomenclature checker.
Hum Mutat. 2008;29:6–13.
27. LUMC Mutalyzer 2.0.23 [Internet]. The aim of this program suite is to
support checks of sequence variant nomenclature according to the
guidelines of the human genome variation society. [cited 2017 Mar 5].
Available from: https://www.mutalyzer.nl/.
28. PolyPhen-2: prediction of functional effects of human nsSNPs [Internet].
PolyPhen-2 (Polymorphism Phenotyping v) is a tool which predicts possible
impact of an amino acid substitution on the structure and function of a
human protein using straightforward physical and comparative considerations.
[cited 2017 Mar 5]. Available from: http://genetics.bwh.harvard.edu/pph2/
29. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat
Protoc. 2009;4:1073–81.
30. SIFT Home [Internet]. SIFT predicts whether an amino acid substitution
affects protein function. SIFT prediction is based on the degree of
conservation of amino acid residues in sequence alignments derived from
closely related sequences, collected through PSI-BLAST. [cited 2017 Mar 5].
Available from: http://sift.jcvi.org/
31. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods. 2014;11:361–2.
32. MutationTaster [Internet]. [cited 2017 Mar 5]. Available from: http://www.
mutationtaster.org/
Raju et al. BMC Cardiovascular Disorders          (2019) 19:174 Page 9 of 10
33. MutationAssessor.org /// functional impact of protein mutations [Internet].
This server predicts the functional impact of amino-acid substitutions in
proteins, such as mutations discovered in cancer or missense
polymorphisms. The functional impact is assessed based on
evolutionary conservation of the affected amino acid in protein
homologs. The method has been validated on a large set (60k) of
disease associated (OMIM) and polymorphic variants. [cited 2017 Mar 5].
Available from: http://mutationassessor.org/r3/
34. ClinVar [Internet]. ClinVar aggregates information about genomic variation
and its relationship to human health. [cited 2017 Mar 5]. Available from:
https://www.ncbi.nlm.nih.gov/clinvar/
35. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet Med. 2015;
17:405–24.
36. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM,
Garrison EP, Kang HM, et al. A global reference for human genetic variation.
Nature. 2015;526:68–74.
37. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, et al.
Genetic testing in the long QT syndrome: development and validation of
an efficient approach to genotyping in clinical practice. JAMA. 2005;294:
2975–80.
38. Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, et al.
Congenital sick sinus syndrome caused by recessive mutations in the
cardiac sodium channel gene (SCN5A). J Clin Invest. 2003;112:1019–28.
39. Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, et al.
Sodium channel mutations and susceptibility to heart failure and atrial
fibrillation. JAMA. 2005;293:447–54.
40. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster
evaluates disease-causing potential of sequence alterations. Nat Methods.
2010;7:575–6.
41. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al.
Clinical and molecular characterization of patients with catecholaminergic
polymorphic ventricular tachycardia. Circulation. 2002;106:69–74.
42. Farrugia A, Keyser C, Hollard C, Raul JS, Muller J, Ludes B. Targeted next
generation sequencing application in cardiac channelopathies: analysis of a
cohort of autopsy-negative sudden unexplained deaths. Forensic Sci Int.
2015;254:5–11.
43. Nunn LM, Lopes LR, Syrris P, Murphy C, Plagnol V, Firman E, et al. Diagnostic
yield of molecular autopsy in patients with sudden arrhythmic death
syndrome using targeted exome sequencing. Europace. 2016;18:888–96.
44. Cheng J, Tester DJ, Tan B-H, Valdivia CR, Kroboth S, Ye B, et al. The common
African American polymorphism SCN5A-S1103Y interacts with mutation
SCN5A-R680H to increase late Na current. Physiol Genomics. 2011;43:461–6.
45. Winkel BG, Yuan L, Olesen MS, Sadjadieh G, Wang Y, Risgaard B, et al. The
role of the sodium current complex in a nonreferred nationwide cohort of
sudden infant death syndrome. Heart Rhythm. 2015;12:1241–9.
46. Hwang HW, Chen JJ, Lin YJ, Shieh RC, Lee MT, Hung SI, et al. R1193Q of
SCN5A, a Brugada and long QT mutation, is a common polymorphism in
Han Chinese. J Med Genet. 2005;42:e7.
47. Eddy C-A, MacCormick JM, Chung S-K, Crawford JR, Love DR, Rees MI, et al.
Identification of large gene deletions and duplications in KCNQ1 and
KCNH2 in patients with long QT syndrome. Heart Rhythm. 2008;5:1275–81.
48. Bansal V, Libiger O. A probabilistic method for the detection and
genotyping of small indels from population-scale sequence data.
Bioinforma Oxf Engl. 2011;27:2047–53.
49. Crotti L, Lewandowska MA, Schwartz PJ, Insolia R, Pedrazzini M, Bussani E, et
al. A KCNH2 branch point mutation causing aberrant splicing contributes to
an explanation of genotype-negative long QT syndrome. Heart Rhythm.
2009;6:212–8.
50. Zhang L, Vincent GM, Baralle M, Baralle FE, Anson BD, Benson DW, et al. An
intronic mutation causes long QT syndrome. J Am Coll Cardiol. 2004;44:
1283–91.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Raju et al. BMC Cardiovascular Disorders          (2019) 19:174 Page 10 of 10
